title: [Update on chemotherapy for bladder cancer. Update 2010].
abstract: This review summarizes results of neoadjuvant and adjuvant trials for locally advanced bladder cancer as well as data on systemic chemotherapy for metastatic urothelial cancer. Increasing attention has been drawn to targeted cancer therapies in the treatment of urothelial cancer in recent years. In future, molecular profiling will play a major role as a means to tailor individual therapy.
authors.affiliation: Urologische Klinik und Poliklinik , Klinikum rechts der Isar, Technische Universität München, München.
authors.forename: M M
authors.initials: MM
authors.lastname: Heck
authors.forename: J E
authors.initials: JE
authors.lastname: Gschwend
authors.forename: M
authors.initials: M
authors.lastname: Retz
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage* / Q000009:adverse effects; D002295:Carcinoma, Transitional Cell / Q000188:drug therapy* / Q000235:genetics / Q000401:mortality / Q000473:pathology; D017024:Chemotherapy, Adjuvant; D018572:Disease-Free Survival; D016503:Drug Delivery Systems; D006801:Humans; D020360:Neoadjuvant Therapy; D009367:Neoplasm Staging; D016032:Randomized Controlled Trials as Topic; D016896:Treatment Outcome; D001749:Urinary Bladder Neoplasms / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology